...
首页> 外文期刊>American Journal of Physiology >Dopaminergic control of angiotensin II-induced vasopressin secretion in vitro.
【24h】

Dopaminergic control of angiotensin II-induced vasopressin secretion in vitro.

机译:在体外多巴胺能控制血管紧张素II诱导的加压素分泌。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Because dopamine influences arginine vasopressin (AVP) release, the present studies were designed to ascertain the dopamine receptor subtype that potentiates angiotensin II-induced AVP secretion in cultured hypothalamo-neurohypophysial explants. Dopamine (a nonselective D1/D2 agonist), apomorphine (a D2 D1 agonist), and SKF-38393 (a selective D1 agonist) dose dependently increased AVP secretion. Maximal AVP release was observed with 5 microM dopamine, 307 +/- 66% . explant-1 . h-1, 1 microM SKF-38393, 369 +/- 41% . explant-1 . h-1, and 0.1 microM apomorphine, 374 +/- 67% . explant-1 . h-1. Selective D1 antagonism with 1 microM SCH-23390 blocked AVP secretion to values no different from basal. Domperidone (D2 antagonist), phenoxybenzamine (nonselective adrenergic antagonist), and prazosin (alpha1-antagonist) failed to prevent release. D1 antagonism also prevented AVP secretion to 1 microM angiotensin II [angiotensin II, 422 +/- 87% . explant-1 . h-1 vs. angiotensin II plus SCH-23390, 169 +/- 28% . explant-1 . h-1 (P < 0.05)], but D2 and alpha1-adrenergic blockade did not. In contrast, AT1 receptor inhibition with 0.5 microM losartan blocked angiotensin II- but not dopamine-induced AVP release. AT2 antagonism had no effect. Although subthreshold doses of the agonists did not increase AVP secretion (0. 05 microM dopamine, 133 +/- 44% . explant-1 . h-1; 0.01 microM SKF-38393, 116 +/- 26% . explant-1 . h-1;and 0.001 microM angiotensin II, 104 +/- 29% . explant-1 . h-1 ), the combination of dopamine and angiotensin II provoked a significant rise in AVP [420 +/- 83% . explant-1 . h-1 (P < 0.01)]. Similar results were observed with SKF-38393 and angiotensin II, and the AVP response was blocked to basal levels by either D1 or AT1 antagonism. These findings support a role for D1 receptor activation to increase AVP release and mediate angiotensin II-induced AVP release within the hypothalamo-neurohypophysial system. The data also suggest that the combined subthreshold stimulation of receptors that use distinct intracellular pathways can prompt substantial AVP release.
机译:因为多巴胺会影响精氨酸加压素(AVP)的释放,所以本研究旨在确定在培养的下丘脑-神经下垂性外植体中增强血管紧张素II诱导的AVP分泌的多巴胺受体亚型。多巴胺(非选择性D1 / D2激动剂),阿扑吗啡(D2 D1激动剂)和SKF-38393(选择性D1激动剂)剂量依赖性地增加AVP分泌。用5 microM多巴胺(307 +/- 66%)观察到最大AVP释放。外植体1。 h-1,1 microM SKF-38393,369 +/- 41%。外植体1。 h-1和0.1 microM阿扑吗啡,374 +/- 67%。外植体1。 h-1。具有1 microM SCH-23390的选择性D1拮抗作用可将AVP分泌阻止至与基础无差异。多潘立酮(D2拮抗剂),苯氧基苯甲胺(非选择性肾上腺素拮抗剂)和哌唑嗪(α1拮抗剂)未能阻止释放。 D1拮抗作用还阻止AVP分泌至1 microM血管紧张素II [血管紧张素II,422 +/- 87%。外植体1。 h-1与血管紧张素II加SCH-23390的比值,169 +/- 28%。外植体1。 h-1(P <0.05)],但D2和α1-肾上腺素能受体阻滞剂没有。相反,用0.5 microM氯沙坦抑制AT1受体可阻断血管紧张素II,但不会阻断多巴胺诱导的AVP释放。 AT2拮抗作用无效。尽管亚阈值剂量的激动剂并没有增加AVP分泌(0. 05 microM多巴胺,133 +/- 44%。explant-1。h-1; 0.01 microM SKF-38393,116 +/- 26%。explant-1。 h-1; 0.001 microM血管紧张素II,104 +/- 29%;外植体1. h-1),多巴胺和血管紧张素II的组合引起AVP的显着增加[420 +/- 83%。外植体1。 h-1(P <0.01)]。用SKF-38393和血管紧张素II观察到相似的结果,并且A1拮抗作用被D1或AT1拮抗作用阻断至基础水平。这些发现支持D1受体激活在下丘脑-神经垂体系统内增加AVP释放并介导血管紧张素II诱导的AVP释放的作用。数据还表明,结合使用不同细胞内途径的受体的阈下刺激可以促使AVP大量释放。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号